A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression.

Trial Profile

A randomized open-label Phase II study of letrozole plus afatinib (BIBW2992) versus letrozole alone in first-line treatment of advanced ER+, HER2- postmenopausal breast cancer with low ER expression.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Oct 2017

At a glance

  • Drugs Afatinib (Primary) ; Letrozole
  • Indications Breast cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Oct 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
    • 10 Oct 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Dec 2017.
    • 25 Apr 2017 Planned primary completion date changed from 1 Mar 2017 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top